Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.30 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.30 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12166178 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAPOLBKMT2A | |
| SCHEMBL12166176 | 0.85 | GAA (0.40) | LMNAKMT2A | |
| SCHEMBL12166163 | 0.84 | EPHX1 (0.40) | KMT2A | |
| SCHEMBL15362522 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAPOLB | |
| SCHEMBL12166171 | 0.82 | EPHX2 (0.46) | LMNAKMT2A | |
| SCHEMBL15362523 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNA | |
| SCHEMBL15362480 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNA | |
| SCHEMBL12166164 | 0.82 | PDE4B (0.34) | — | |
| SCHEMBL12166179 | 0.82 | EPHX2 (0.37) | SMN1; SMN2LMNAPOLBKMT2A | |
| SCHEMBL12166177 | 0.81 | PIK3CD (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361994-B2 | Primary amine diazeniumdiolate heterocyclic derivatives | MERCK SHARP & DOHME CORP (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120232039-A1 | PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232039-A1 | PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | EDNRA, PAH, EDNRB | SMN1; SMN2 3116/4885LMNA 578/4885POLB 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.